Hypertension is a major public health issue and leading cause of cardiovascular disease globally. It is responsible for about half of heart disease and stroke deaths. The number of hypertensive individuals in India is expected to nearly double by 2025. Chronic kidney disease (CKD) is a major complication of hypertension, with hypertension being the primary cause of end stage renal disease. Strict blood pressure control and use of renin-angiotensin system inhibitors are important for slowing the progression of CKD and reducing proteinuria. Calcium channel blockers, particularly non-dihydropyridine types like cilnidipine, have beneficial effects on renal function through reduction of intraglomerular pressure and antioxidant properties independent of blood pressure
Management of coronary disease in diabetes - Is it different?Dr Vivek Baliga
The management of diabetes and coronary artery disease go hand in hand. This presentation by Dr Vivek talks on whether it varies from usual management.
Management of coronary disease in diabetes - Is it different?Dr Vivek Baliga
The management of diabetes and coronary artery disease go hand in hand. This presentation by Dr Vivek talks on whether it varies from usual management.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
2. Hypertensio
n is a major
public
health issue
and one of
the most
common
lifestyle dis
eases
About 1 in 3
adults have
high blood
pressure,
but many
are unaware
of it -
”silent
killer ”
Globally
cardiovascul
ar disease
accounts for
approximate
ly 17 million
deaths
(1/3rd of the
total
death)/year.
Hypertensio
n is
responsible
for at least
45% of
deaths due
to heart
disease, and
51% of
deaths due
to stroke.
In India-
number of
hypertensiv
e individuals
is
anticipated
to nearly
double from
118 million
in 2000 to
214 million
by 2025.
Heart India, Vol 2 / Issue 4 / Oct-Dec 2014: World Health Organization 2013:
Hypertension – Global and Indian Scenario
3. 39%
15% 13%
33%
Incidence of ESRD by Cause
Primary Diagnosis for Patients Who Start Dialysis
Hypertension
Other
Diabetic
Nephropathy
Diabetic Nephropathy
+
Hypertension
8. Effects of High BP on Renal Function
With Advancing Age
Phase II
Phase III
Phase IV
Phase V
in RVR due to functional disturbance of renal vasculature: ? active vasoresponse to
endogenous angiotensin II, norepinephrine
Further in RVR; both functional and structural disturbance in renal vasculature;
preservation of GFR (glomeruli may be ischemic); in FF; microalbuminuria
Further in RVR; structural disturbance involving both renal vasculature and glomeruli
(arteriolar nephrosclerosis); in perfusion disproportionately greater than filtration;
sustained in FF; proteinuria
Critical in renal mass; in RVR ( in afferent arteriolar resistance); in PGC; progressive
in GFR; nephrosclerosis, glomerulosclerosis
Chronic renal insufficiency end-stage renal disease
BP=blood pressure, FF=filtration fraction, GFR=glomerular filtration rate, PGC =glomerular capillary pressure,
RVR=renal vascular resistance.
Adapted from Bauer JH, Reams GP. Am J Hypertens 1989; 2: 173S-178S.
Age (y)
(20-30)
(30-40)
(40-50)
(50+)
Phase I
9. Hypertension due CKD due to Hyper-
to CKD tension
(i) Common (i) Less Common
(ii) H/O Kidney disease (ii) H/O Hypertension prec-
Preceeds hypertension eeds Kidney disease
(iii) Cardiomegaly, HT (iii) Cardiomegaly, HT
retinopathy less common retinopathy more common
(iv) USG: Kidneys contr- (iv) Less contracted>9 cms
acted <9cm. CMD lost CMD preserved
(v) Prognosis: Worse (v) Good
12. Blood Pressure Is a Major Risk Factor for Renal Death
An Analysis of 560 352 Participants From the Asia-Pacific Region
O'Seaghdha CM, et al. Hypertens 2009; 54:509-515.
13. Lower BP Slows Decline in GFR
95 98 101 104 107 110 113 116 119
MAP (mmHg)
GFR
(mL/min/year)
130/85 140/90
Untreated
HTN
0
-2
-4
-6
-8
-10
-12
-14
Bakris GL, et al. Am J Kidney Dis. 2000
But newer studies suggest there
may be other dangers down here
14. Multiple antihypertensive agents are
required to achieve target BP
Majority of the patients require more > 2 drugs to
achieve goal BP
Bakris G et al. AJKD. 2000;36:646-61.Brenner BM et al. NEJM. 2001;345:861-9.Lewis EJ et al. 2001;345:851:60.
15.
16. Morbidity and Mortality Along the
Renal Continuum
Risk Factors
Diabetes
Hypertension
Endothelial
Dysfunction
Micro-
albuminuria
Macro-
proteinuria
Nephrotic
Proteinuria
End-Stage
Renal Disease
CVD
Death
17.
18. GLOMERULUS
GLOMERULUS
AFF
EFF
AFF
EFF
TUBULES TUBULES
Afferent arteriolar dilatation by amlodepine
andhydrallazine leading to increase
intraglomerular(glmP)
Pressure and more proteinuria.
glmP
proteins
glmP
Efferent arteriolar dilatation by ACEIs, ARBs
&,cilnidipine leading to drop in
intraglomerular pressure and no proteinuria
with renoprotection
decrease
increase
19. In the MDRD study, for each 1 g/day reduction in protein
excretion during the first four months, the rate of decline in
GFR fell by 0.9 to 1.3 mL/min per year
The fall in proteinuria was related to the blood pressure,
being more prominent in those with more
aggressive blood pressure control.
●Among patients with protein excretion ≥3 g/day in the REIN
trial, the rate of decline in GFR correlated inversely with the
degree of proteinuria reduction and the magnitude of benefit
seemed to exceed that expected for the degree of blood
pressure lowering .
20. eGFR, UAE and relative risk : Heat map
Categories
Rank Color
Levey A, de Jong P, Coresh J et al. KDIGO. Kidney Int. 2011;80:17-28
No risk/ CKD
Moderate risk
High risk
Very high risk
Composite ranking for
relative risk by GFR and
albuminuria (KDIQO
2009)
21. Association of Kidney Function and
Albuminuria
• ARIC study showed that even mildly increased ACR
(9.14-14.0 mg/g) was associated significantly with
incident hypertension
• Other studies also have shown that higher
normoalbuminuria (ACR >5 or 8.5) also can decline
GFR and increase ESRD and CVD risk
Huan g et al. Am J Kidney Dis. 2015;65(1):58-66.
Hallan SI et al. J AM Soc Nephrol. 2009;20(5):1069:77.
Antihypertensives with anti-albuminuric effect may
have a preference over other antihypertensives with no
anti-albuminuric effect?
The Atherosclerosis Risk in Communities (ARIC) Study with 4,378 participants (45.6%) with prevalent
hypertension at baseline and 2,175 incident hypertension cases during a median follow-up of 9.8 years
22. Targets for blood pressure control in
CKD
Regardless of the cause of CKD antihypertensive treatment should be
initiated to achieve BP goal
Target population Goal BP
CKD (Diabetic/ nondiabetic)
and AER (or ACR) <30 (A1)
≤140/90 mm Hg
CKD (Diabetic/ nondiabetic)
and AER (or ACR) >30 (A2 or A3)
≤130/80 mmHg
Kidney transplant recipients ≤130/80 mmHg
Children with CKD 90th percentile for age, sex,
height
50th percentile for age, sex,
height with any proteinuria
Elderly with CKD Individualize (consider a higher goal,
especially for age >80 y)
23. Drugs That Can Reduce Proteinuria
ALL ACEs/ARBs
NONDIHYDROPYRIDINES (CCBs)
PENTOXYPHYLLINE
SPIRONOLACTONE, INDAPAMIDE
LACINIDEPINE - Not very marked
It takes about 2-3 months for
significant proteinuria
reduction and all act through
reducing PGC
24. RAAS blockade as Initial choice of
therapy?
• Multiple trials powered for kidney outcomes
demonstrate an advantage of RAAS blockade for
slowing progression of CKD and reducing
proteinuria in patients with diabetes and
consequent nephropathy
• But, all of the appropriately powered trials
that demonstrate this effect are in
individuals with advanced Stage 3 CKD who
also had proteinuria > 500 mg/day
Brenner BM et al .N Engl J Med. 2001;345:861-869 , Lewis EJ et al . N Engl J Med.
2001;345:851-860, Lewis EJ et al. N Engl J Med. 1993;329:1456-1462
25. Reduction in
renal
function
Lower Ang-II
level reduces
efferent
vasomotor
tone
resulting in
reduced GFR
and renal
function
Hypotension
Suppression
of Ang-II in
patients
with
circulatory
failure may
cause severe
hypotension
Hyperkalemia
ACE-i
decrease
aldosteron
e levels
This blunts
renal
potassium
excretion
Elevated
bradykinin
ACE-i leads to
accumulation
of bradykinin
and other
pro-
inflammatory
peptides
26. What about CKD with ACR < 30
mg/gm, without diabetes?
No clear drug preference including
RAAS blockers
Treat similar to normal hypertensives
NICE 2014 guidelines
27. Non dihydropyridine calcium channel blocker
The non-dihydropyridine calcium channel blockers, such
as diltiazem and verapamil, have significant
antiproteinuric effects in patients with proteinuria. By
comparison, the dihydropyridines, such
as amlodipine and nifedipine, have a variable effect on
proteinuria, ranging from an increase to no effect to a
fall in protein excretion.
The mechanisms underlying this varied effect on
proteinuria may include preferential afferent arteriolar
dilatation with dihydropyridines,which allows more of
the aortic pressure to be transmitted to the glomerulus,
and differential abilities of the non-dihydropyridine and
dihydropyridine calcium channel blockers to alter renal
autoregulation, the permeability of the glomerulus, and
perhaps other factors.
28. Differences between non-dihydropyridine and
dihydropyridine calcium channel blockers were
illustrated in a systematic review of 23 studies
that adjusted for sample size, study length, and
baseline values.Based upon an analysis of
monotherapy in 510 patients,
non-dihydropyridines decreased mean
proteinuria by 30 percent and dihydropyridines
increased proteinuria by 2 percent.
Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium
antagonist subclasses on markers of nephropathy progression.
Kidney Int 2004; 65:1991.
29. Slowing Down CKD
Progression – Where
are we now?
Blood pressure reduction
RAS Inhibition
Low Protein Diet
SGLT2 Inhibitors
GLP-1 Agonist
MRAs
Statins
Anemia Correction
Smoking Cessation
Vitamin D ?
30.
31. L – type = Long lasting
L-type currents are long lasting (slow inactivation rate)
and are blocked by all CCBs
They are found in Cardiac & Vascular tissues
They are absent in Renal tissues
T – type = Transiently activated
T-type currents are transient (fast inactivation)
They are present in Renal tissue
N – type = Neuronal
The N-type currents are found primarily in neurons
where they initiate
neurotransmission by releasing norepinephrine from
peripheral sympathetic nerve endings
They are also present in Renal tissue
P or Q-type
They are neuronal type of Calcium channels
They were recently detected in Arterioles
32.
33. Sympathetic
nerve
activity
(N-type Ca++ channels)
Leptin
Obesity
Increased Insulin resistance
H
Y
P
E
R
T
E
N
S
I
O
N
Stress
Heart
Peripheral artery
Kidney
Skeletal muscle
Leads to increase in :
• Cardiac output
Vascular resistance
Na+ retention
Renin-Angiotensin System
Cardiovascular Therapeutics 27 (2009) 124–139
35. RSSDI
Recommendations
for Management of
Hypertension in
Patients with
Diabetes Mellitus
2022
35
● Dietary & Lifestyle
Recommendations
● Goal BP & Initial Drug
Therapy
● Individual Drug classes and
their benefits
● Pharmacotherapy for HTN management
in Diabetes - Recommendations
RSSDI
36. 36
Pharmacotherapeutic recommendations in diabetic
hypertension
Individual profile of the patient and their response to the treatment
must be evaluated for the selection of the most suitable treatment
agent for hypertensive management (grade A)
ARBs, either alone or in combination with CCBs, can be used for BP
control in diabetic patients (grade A)
Combination therapy of ARB and CCB is recommended to be
initiated in hypertensive patients for better BP control, reducing
risks of complications, and better patient adherence (grade B)
ARBs must be preferred over ACEi in diabetic patients with
hypertension, telmisartan or azilsartan being selected as the first-
line agent (grade B)
37. 37
Pharmacotherapeutic recommendations in diabetic
hypertension
In patients at the risk of CVDs, renal disorders, or cerebrovascular disorders,
combination therapy must be preferred for the reduction of patient mortality (grade
B)
CCBs must be preferred over BB and thiazides in combination therapy with ARBs.
Cilnidipine is a comparatively more effective and safer novel molecule as compared
to conventional CCBs for Indian diabetic hypertensive patients (grade A)
The use of BB and thiazide diuretics must be avoided in patients with DM and
hypertension because of their potential to cause cardiovascular events and
hyperglycaemia, respectively (grade A)
Monitoring of electrolyte levels, serum potassium, and creatinine levels, as well as
regular evaluation of kidney function, is recommended for patients with diabetic
hypertension based on the choice of treatment agents and their risk profile (grade B)
39. Reno-protective and antioxidant effects of cilnidipine
in hypertensive patients
The urinary albumin, 8-hydroxy-
20-deoxyguanosine (OHdG) and
liver-type fatty-acid-binding
protein (L-FABP) to creatinine
ratios significantly decreased in
the cilnidipine group compared
with those in the amlodipine
group.
The reductions in urinary
albumin, 8-OHdG and L-FABP
were not correlated with the
change in systolic BP.
Cilnidipine, but not amlodipine, ameliorated urinary albumin excretion and
decreased urinary 8-OHdG and L-FABP in the hypertensive patients. Cilnidipine
probably exerts a greater reno-protective effect through its antioxidative properties
Hypertension Research (2012) 35, 1058–1062; doi:10.1038/hr.2012.96; published online 5 July 2012
40. Cilnidipine – Reduction of Proteinuria
CARTER
Study
• Cilnidipine was more beneficial than amlodipine as additional medication for
hypertensive patients who had kidney disease associated with significant
proteinuria
• Combination therapy with cilnidipine and an ARB ameliorated urinary albumin
excretion more potently than ARB monotherapy
• It is suggested that cilnidipine rather than an amlodipine should be recommended
Conclusion